Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Balstilimab + Botensilimab + Vitamin C |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Balstilimab | AGEN-2034|AGEN2034 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Balstilimab (AGEN2034) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 ligand (CD274), potentially resulting in enhanced anti-tumor immune response (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3086-3086). | |
| Botensilimab | AGEN1181|AGEN 1181|AGEN-1181 | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 | Botensilimab (AGEN1181) is an antibody that targets CTLA4, potentially resulting in increased anti-tumor immune response (Journal for ImmunoTherapy of Cancer 2021;9). | |
| Vitamin C | L-ascorbic acid |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06336902 | Phase I | Balstilimab + Botensilimab + Vitamin C | Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients with KRAS-Mutant Metastatic Colorectal Cancer | Recruiting | USA | 0 |